×
About 121,302 results

ALLMedicine™ Detailed topics Center - Drugs

KOSELUGO™ (selumetinib) - Official Website‎
https://www.koselugo.com

Learn More Information About Now FDA-Approved KOSELUGO On The Official Site. Resources Available. Important Safety Info. Indication Info. Download Prescribing Info. Access 360 Program. Insurance coverage: Financial Support Info, Access 360 Program.

FDA approves niraparib for first-line maintenance of advanced ovarian cancer
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer
FDA

Apr 28th, 2020 - The Food and Drug Administration approved niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.

FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-capmatinib-metastatic-non-small-cell-lung-cancer
FDA

May 5th, 2020 - On May 6, 2020, the Food and Drug Administration granted accelerated approval to capmatinib (TABRECTA, Novartis) for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.

Retevmo™ (selpercatinib)‎ - Visit The Official Site‎
https://www.retevmo.com/

View Safety & Prescribing Information On The Official Patient Site. Learn How Retevmo™ Works And How It May Help Eligible Patients. Savings & Support. Dosing and Administration. About RETEVMO™. Types: Patient Resources, Treatment Information, Safety Information.

DARZALEX Faspro™ - Info for Physicians‎
https://www.darzalexhcp.com

(daratumumab and hyaluronidase human-fihj) Learn More at the Official Physician Site. Prescription Assistance. Patient Support Program. Dosing Admin & Safety. Janssen CarePath. Official Physician Site. Learn About Multiple MOAs. Patient Dosing Schedule.

TABRECTA™ (capmatinib) - Now Approved - HCP Site‎
https://www.hcp.novartis.com/products/tabrecta/met-exon-14-skipping-mutation-nsclc/efficacy/?site=MTX-1228793GK104516&source=01030&gclid=EAIaIQobChMIqfz855_K6QIVCZezCh1p0gOqEAAYAiAAEgJWYPD_BwE&gclsrc=aw.ds

HCPs, Visit The Official Site For Information About TABRECTA™ As A Treatment Option. See If TABRECTA™ Could Be Right For Your Patients. Full Safety Profile. Patient Co-Pay Program. Mechanism Of Action. Newly FDA Approved. Official HCP Website. Clinical Trial Data.

ZEJULA® (niraparib) HCP Site - Oral Treatment Option‎
https://www.zejula.com/en/hcp

Visit our website to find information on efficacy, safety, and dosing. HCP Resources. Treatment Sequencing. Patient Stories. Prescribing Information. Dose Modification. Zejula ovarian cancer niraparib Zejula

A First-line Oral Treatment for Certain People with Gaucher Disease Type 1
http://www.cerdelga.com/healthcare-professionals.html

CERDELGA is a glucosylceramide synthase inhibitor indicated for the long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.

ADEMPAS (riociguat) tablets
http://adempas-us.com/hcp/

Adempas (riociguat). Visit Adempas-US.com to see full safety and prescribing information, including Boxed Warning. Learn about Adempas and the Aim Patient Support Program.

ACNIZIL™ topical gel
https://www.henryschein.com/us-en/Medical/ShopExp/Acnizil.aspx

Acnizil™ is a new first-line therapy product for mild to severe acne. It is made from a proprietary silver solution

Abbott RealTime IDH1
https://www.molecular.abbott/us/en/products/oncology/realtime-idh1

An in vitro polymerase chain reaction (PCR) assay for the qualitative detection of single nucleotide variants (SNVs)

ACTEMRA® (tocilizumab) intravenous drip infusion or injection
https://www.actemrahcp.com/

Find valuable ACTEMRA® (tocilizumab) information, including an ACTEMRA® dosing calculator, RA patient brochure, ACTEMRA® prescription guide and the ISI. IMPORTANT SAFETY INFORMATION-RA: ACTEMRA is a prescription medicine called an interleukin-6 (IL-6) receptor antagonist.

AcrySof IQ Cataract IOLs | myalcon.com
https://www.myalcon.com/products/surgical/acrysof-iq-cataract-iols/index.shtml

Explore AcrySof IQ intraocular lenses for your cataract surgery and the AcrySof® Advantage at myalcon.com.

ADLYXIN (lixisenatide)
https://www.adlyxinpro.com/

Learn about Adlyxin™ (lixisenatide) injection, a GLP-1 receptor agonist to help improve glycemic control in adults with type 2 diabetes indicated as an adjunct to diet and exercise.

ABILIFY MAINTENA® (aripiprazole) injection
https://abilifymaintenahcp.com/

ABILIFY MAINTENA for the treatment of schizophrenia and the maintenance treatment of bipolar I disorder in adult patients. See full Safety and Prescribing Information, including BOXED WARNING.

Adcirca® (tadalafil)
http://www.adcirca.com/hcp/index.aspx

ADCIRCA is a trademark of Eli Lilly and Company. http://pi.lilly.com/us/adcirca-ppi.pdf. Please see Important Safety Information and Full Prescribing Information.

ADPKD Treatment | JYNARQUE™ HCP (tolvaptan) tablets
https://www.jynarquehcp.com/

The first and only FDA-approved treatment indicated to slow kidney function decline and kidney cyst growth in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).

ACTICLATE® (doxycycline hyclate USP) tablets
http://aquapharm.com/acticlate.php

ACTICLATE® (doxycycline hyclate USP) Tablets are indicated for adjunctive therapy in severe acne. Click here for Full Prescribing Information for ACTICLATE® Tablets. Important Safety Information Regarding ACTICLATE® (doxycycline hyclate USP) Tablets, 150 mg and 75 mg.

ABIOMED | Impella RP
http://www.abiomed.com/impella/impella-rp

The Impella RP® System is indicated for providing temporary right ventricular support for up to 14 days in patients with a body surface area